We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

In the latest trading session, Merck (MRK) closed at $89.23, marking a +1.86% move from the previous day. This move outpaced the S&P 500's daily loss of 1.97%. Meanwhile, the Dow experienced a drop of ...

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.